Broadening T cell control in atopic dermatitis

The two atopic dermatitis programs that read out last week offer glimpses of what’s possible outside the cytokine inhibition paradigm behind blockbusters Dupixent and Rinvoq. Newer candidates from Corvus and Sanofi are broadening T cell subtype inhibition via upstream T cell activation targets, which could unlock options for treatment-refractory patients, and provide more durable therapeutic responses across the board.

On Jan. 20, investors rewarded Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) for the Phase I efficacy of its oral ITK inhibitor soquelitinib in a cohort of 24 patients who had failed at least one prior topical or systemic therapy, with the company’s shares rising 166% to $21.41 on the news. ...